Riedl Khursigara, M.; Goss, A. C.; Kost-Alimova, M.; Keller, K.; De Mata, C. D.; Muraleedharan, R.; Collantes, E. R.; Brown, M.; Grinkevich, E.; Arines, F. M.; Lin, J.; Byrne, P.; Bazua Valenti, S.; Morici, E.; Roignot, J.; Zavras, J.; Silverman, B. R.; Ignacio, J. C.; Myung, Y.; Kwon, S.; Nelson, A.; Yoo, H.; Melanson, M.; Racette, M.; Padovano, V.; Alper, S. L.; Carey, D.; Udeshi, N. D.; Carr, S. A.; Dvela-Levitt, M.; Narimatsu, T.; Sakuno, G.; Correa, V. S. M. C.; Efstathiou, N. E.; Ntentakis, D. P.; Cao, T.; Dong, Z.; Nguyen, K. T.; Rodrigues Menezes, C.; Kurumbail, R.; Kazmirski, S.; Xiao

Severe proteinopathies, such as retinitis pigmentosa, a form of inherited blindness, are driven by genetic mutations that overwhelm the quality control of the post-endoplasmic reticulum (post-ER) secretory pathway, causing toxic protein accumulation. Here, we identify a therapeutic node defined by a hetero-oligomeric cargo receptor complex consisting of TMED7, 2, 9, and 10. This entrapment complex anchors structurally and functionally diverse mutant clients within the early secretory pathway via TMED7 binding to the integral Golgi protein GRASP55. Disruption of the entrapment complex results in the clearance of accumulated protein cargoes. In vivo ablation of the entrapment node via inducible genetic deletion or via the small molecule BRD7635 reverses histopathological hallmarks and rescues functional deficits in clinically distinct proteinopathies of the kidney and the eye, including mitigating vision loss in a mouse model of retinitis pigmentosa.